NRS-02 - Neurogenic Inflammation and Long-Term COVID

Wednesday, September 3, 2025

7:30 AM - 8:25 AM PST

Location: Nolita (Level 4)

CE: Credit Hours: 1 | Pharmacotherapy: 0 | Mate: 0

Co-Presenter(s)

Joseph V. Pergolizzi, Jr., MD, MBA

Sr Advisor
NEMA Research
Naples, Florida
Robert B. Raffa, BChE, BS, MS, PhD

Professor Emeritus
(1) Temple Univ Sch Pharmacy (2) Univ AZ College Pharmacy (3) Neumentum (4) Enalare
Temple University
Tucson, Arizona
Srinivas Nalamachu, MD

President
Analgesic Clinical Research LLC
Kansas City University of Medicine and Biosciences
Overland Park, Kansas
Frank Breve, PharmD, MBA

President and CEO - Clinical Pharmacist Consultant
Mid Atlantic PharmaTech Consultants, LLC
Temple University School of pharmacy
Ventnor City, New Jersey

Long Covid, the prolonged sequelae of SARS-CoV-2 infection in some people, is associated with a myriad of symptoms, including neurological manifestations such as neurogenic inflammation and painful neuropathy. This Session reviews the current understanding of neuropathic pain in Long Covid patients, exploring the potential mechanisms, clinical presentations, and therapeutic strategies. We discuss the implications of these findings for both clinical practice and future research. While current treatments focus on symptomatic relief, understanding the underlying mechanisms could lead to more targeted therapies.

Learning Objectives:

Understand the effect on an affected patient's quality of life.
Understand some of the underlying pathophysiology.
Describe the pharmacologic treatment options.
Describe the non-pharmacologic treatment options.